IDEAYA Biosciences Files Form 3 for New CFO’s 250k Stock Options

Rhea-AI Filing Summary

SEC Form 3 filing for IDEAYA Biosciences (IDYA): Newly appointed Chief Financial Officer Joshua Bleharski has disclosed his initial beneficial ownership. The filing shows 250,000 stock options with an exercise price of $20.05 per share. Vesting begins 25 % on May 1 2026, with the remaining shares vesting monthly in equal installments over 36 months, reaching full vesting by May 1 2029. No non-derivative common shares are reported at this time, and the options are held directly. This Form 3 is procedural, establishing the CFO’s ownership under Section 16(a) of the Exchange Act; it does not include financial performance data or indicate any corporate transactions.

Positive

• Alignment of incentives: 250,000 stock options tie the new CFO’s compensation to long-term share performance.

Negative

• Potential dilution: The option grant adds up to 250,000 shares to the company’s fully diluted share count if exercised.

Insights

Corporate Governance Expert

TL;DR: Routine Form 3; CFO granted 250k options at $20.05—neutral governance disclosure.

The filing merely establishes Mr. Bleharski’s Section 16 status and discloses a standard equity incentive package. A 250,000-share option grant aligns the new CFO’s interests with shareholders through long-term, performance-contingent compensation. The four-year vesting schedule is typical for tech-biotech issuers, encouraging retention. At roughly 0.4 % of IDYA’s ~64 million outstanding shares (latest 10-Q), dilution risk is minimal. No cash transactions, sales, or additional share ownership are reported, so there is no direct market impact. Investors should view this as neutral housekeeping rather than a catalyst.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bleharski Joshua

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/27/2025

3. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	05/29/2035	Common Stock	250,000	$20.05	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from May 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Joshua Bleharski	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IDEAYA Biosciences (IDYA) disclose in the Form 3?

The company reported that new CFO Joshua Bleharski holds 250,000 stock options with a $20.05 exercise price.

When do the IDYA CFO’s stock options vest?

25 % vest on May 1 2026; the remainder vests monthly until full vesting on May 1 2029.

Are any non-derivative IDYA shares owned by the CFO?

No. The Form 3 lists no direct or indirect ownership of common stock outside the option grant.

Does the filing signal any corporate transaction or earnings update?

No. It is a routine initial ownership disclosure required under Section 16(a).

Will the stock option grant dilute IDYA shareholders?

If all 250,000 options are exercised, the fully diluted share count would increase by that amount—about 0.4 % of shares outstanding.